Drug Database
KD

KD2-305 (KD2305 / KD 2305)

✓ Approved

Meiji Holdings · Recombinant Proteins · Recombinant Proteins

What is KD2-305?

KD2-305 is a recombinant proteins developed by Meiji Holdings. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesKD2305, KD 2305
CompanyMeiji Holdings
Drug ClassRecombinant Proteins
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Therapeutic Indications

KD2-305 is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor IX deficiency✓ Approved
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedCardiovascular diabetology. Endocrinology reports2026-10-21

Multidomain Autonomic Dysfunction assessed with COMPASS-31 among patients with type 2 diabetes in Zanzibar: prevalence and associated factors.

Haji Hassan Thabit HT, Ali Ramla Muhidin RM, Khamis Ahmed Gharib AG, Ramaiya Kaushik K et al.

Autonomic dysfunction is an important but frequently under-recognized complication of type 2 diabetes mellitus (T2DM), particularly in settings where objective autonomic testing is not routinely available. The Composite Autonomic Symptom Score-31 (COMPASS-31) provides a practical symptom-based approach for assessing autonomic dysfunction across multiple domains. This study compared socioeconomic, lifestyle, and clinical characteristics among adults with T2DM in Zanzibar according to COMPASS-31-defined autonomic dysfunction and examined factors associated with its presence. This hospital-based cross-sectional study included 665 adults with T2DM attending the diabetes clinic at Mnazi Mmoja Hospital, Zanzibar. Autonomic symptoms were assessed using COMPASS-31, including the orthostatic intolerance, gastrointestinal, and bladder domains. Participants were classified as having autonomic dysfunction when they met the prespecified threshold for dysfunction in at least one assessed domain. Cardiovascular autonomic neuropathy (CAN) was assessed separately using standardized cardiovascular autonomic reflex tests performed with an automated CAN Analyzer and was not included in the COMPASS-31 composite outcome. Modified Poisson regression with robust variance estimation was used to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Overall, 309 participants (46.5%) had COMPASS-31-defined autonomic dysfunction. Orthostatic intolerance was the most common domain, affecting 271 participants (40.8%), followed by gastrointestinal dysfunction in 177 (26.6%) and urinary dysfunction in 123 (18.5%). Separately, 305 participants (45.9%) met the analyzer-based criteria for CAN. In the multivariable analysis, autonomic dysfunction was more prevalent among participants without a family history of diabetes (aPR = 1.37, 95% CI: 1.16-1.61; p < 0.001), those with diabetes duration of ≥ 10 years (aPR = 1.45, 95% CI: 1.14-1.75; p < 0.001), those not using oral hypoglycemic agents (aPR = 1.66, 95% CI: 1.39-1.97; p < 0.001), and those who rarely consumed vegetables or consumed one portion per day (aPR = 1.79, 95% CI: 1.37-2.34; p < 0.001). Approximately half of the adults with T2DM in this tertiary-care population had COMPASS-31-defined autonomic dysfunction. Higher prevalence was associated with no family history of diabetes, longer diabetes duration, non-use of oral hypoglycemic agents, and lower vegetable intake. These findings highlight the potential value of symptom-based autonomic assessment and support further prospective research to better understand the clinical and lifestyle factors associated with autonomic dysfunction among adults with T2DM in Zanzibar.

PMID 42902341
Read full article →
PubMedRevista espanola de cirugia ortopedica y traumatologia2026-10-20

[Translated article] Preoperative weight-adjusted dexamethasone in total knee arthroplasty: Optimizing analgesic efficacy and safety.

Segura-Nuez Julián Carlos JC, Martínez-Delgado Fernando F, Aldabas-Soriano Silvia S, Caballero-Burbano María Jesús MJ

Background Total knee arthroplasty (TKA) is frequently associated with moderate to severe postoperative pain. Dexamethasone (DEX) is widely used as part of multimodal analgesia, although the optimal dose remains uncertain. This study compared the analgesic efficacy of a weight-adjusted intermediate DEX dose (0.3 mg/kg) with a fixed 8 mg dose. Methods In this retrospective cohort study, 577 patients undergoing primary TKA between January 2021 and December 2024 received either 0.3 mg/kg DEX (n = 305) or a fixed 8 mg dose (n = 272) preoperatively. Pain was assessed using a numerical rating scale (NRS, 0-10 points) and the number of 5 mg oxycodone rescue doses at 24 and 48 h postoperatively. C-reactive protein (CRP) and blood glucose were measured at 24 h. Multivariate analyses evaluated the association of age, sex, and DEX dose with pain outcomes. Results Patients receiving 0.3 mg/kg DEX reported significantly lower pain scores than those receiving 8 mg, with mean differences of 1.13 NRS points at 24 h and 1.17 points at 48 h (p < 0.001). Oxycodone rescue use was reduced at both time points (p < 0.001). Older age and male sex were independently associated with lower pain scores. CRP levels at 24 h were lower in the weight-adjusted group, whereas postoperative glucose levels were higher (both p < 0.05). Length of stay did not differ significantly between groups. Conclusion A preoperative, weight-adjusted dexamethasone dose of 0.3 mg/kg provides superior early postoperative analgesia compared with a fixed 8 mg dose after TKA, reducing pain scores and opioid requirements during the first 48 h.

PMID 42901449
Read full article →
PubMedBMC public health2026-10-20

High intention, low uptake: HPV vaccination knowledge, attitudes, and behavior among women attending a tertiary gynecology clinic in Turkey.

Öncü Esra E, Korun Zeynep Ece Utkan ZEU, Yazıcı Melis Gökçe Koçer MGK, Yeşiladalı Mert M et al.

HPV vaccination prevents cervical cancer, yet uptake remains variable, particularly where it is not publicly funded. We assessed HPV knowledge, attitudes, and vaccination behavior - including stated intention, actual uptake, and reasons for non-vaccination - among women attending a gynecology clinic in Istanbul, Turkey. This cross-sectional study enrolled 305 women aged ≥ 18 years at the gynecology clinic of Yeditepe University Hospital between January and April 2026. A structured questionnaire assessed sociodemographics, HPV and vaccine knowledge (scored 0-10 and 0-6), attitudes (seven 5-point Likert items), and vaccination history. Acceptance was defined as agreement with willingness to vaccinate; uptake as self-reported prior vaccination. Multivariable logistic regression identified factors independently associated with each outcome. Mean age was 38.1 ± 10.6 years; 68.5% had university education and 17.4% were healthcare workers. Mean HPV knowledge score was 7.25 ± 1.65, with notable gaps: 36.7% knew HPV is not exclusive to women, 57.4% knew condoms do not fully prevent transmission, and 60.0% understood infection is often asymptomatic. While 86.6% intended to vaccinate, actual uptake was 38.7% - an intention-uptake gap of 47.9% points. Cost was the most cited reason among unvaccinated women (71.0%). Education, knowledge, and preventive gynecological care were not independently associated with uptake; healthcare-worker status was the only independent predictor (aOR 2.01, 95% CI 1.07-3.80; p = 0.030). HPV vaccine acceptance was high but uptake was substantially lower, with cost the most frequent barrier. These findings highlight the intention-uptake gap and specific knowledge deficits relevant for future research.

PMID 42897523
Read full article →
PubMedCirculation2026-10-20

Multimodal KCNQ1 Variant-Effect Maps Define Ion Channel Mechanisms and Disease Risk.

Harvey M Lorena ML, Osborn Ellen E, Lancaster Megan C MC, Smith Jeremy E JE et al.

Variants in the ion channel gene KCNQ1 are the leading cause of congenital long QT syndrome (LQTS), a disorder characterized by QT prolongation and risk of fatal arrhythmias. The expanding use of genetic testing has led to the identification of numerous variants of uncertain significance, complicating clinical interpretation and risk stratification. Functional characterization of KCNQ1 variants is essential to define their role in long QT syndrome and advance precision medicine in cardiovascular care. We generated a nearly comprehensive variant library of 13 403 protein-coding variants in KCNQ1. Using 4 pooled assays followed by high-throughput sequencing, we characterized the variants' effects on cell surface abundance and channel function in both the variant-only and heterozygous states. Case-control analyses and data from large-scale biobanks were used to assess the clinical impact of loss-of-function variants on QT prolongation and long QT syndrome. Heterozygous assay results were used to determine dominant-negative effects, which were also evaluated for association with arrhythmia risk. Protein structural clustering of distinct classes of deleterious variants was analyzed. Across the 4 assays, we generated 49 305 functional measurements of KCNQ1 variants. Of the 13 403 KCNQ1 studied variants, 1757 demonstrated strong pathogenic evidence, and 6660 showed moderate benign evidence. Loss-of-function variants were significantly associated with QT prolongation and long QT syndrome in case-control and biobank analyses. Deleterious variants clustered within distinct structural domains based on their functional classification. A majority of pathogenic variants exhibited dominant-negative effects; these variants were linked to a higher risk of arrhythmia diagnoses than were haploinsufficient variants. This comprehensive KCNQ1 functional atlas provides novel functional evidence for most KCNQ1 variants of uncertain significance. It also reveals mechanistic principles linking genetic variation to ion channel biology and arrhythmia susceptibility, advancing cardiovascular precision medicine.

PMID 42899351
Read full article →
PubMedWorld journal of urology2026-10-18

Mini-PCNL and mini-ECIRS in a solitary kidney population: a single-center experience.

Di Bello Francesco F, Bravo-Balado Alejandra A, Verri Paolo P, Izquierdo Paula P et al.

To quantify the postoperative outcomes, namely complication rates and renal function, of mini-combined endoscopic combined intrarenal surgery (ECIRS) or mini-percutaneous nephrolithotomy (PCNL) within solitary kidney (SK) patients. We relied on a single-centre retrospective database including 658 patients who underwent endourological surgeries for stone treatment, between 2018 and 2025. Endpoints, namely intraoperative and postoperative complications, length of stay (LOS), and renal function were quantified. Based on a median follow-up of 15 months (IQR 6-35), 28 SK patients, for a total of 33 surgeries, were included. Out of 33 surgeries, 18 (55%) consisted of ECIRS and 15 (45%) were PCNL. The rates of SK patients who underwent surgeries ranged from 3% in 2018 to 14% in 2025. Out of all 33 surgeries, 14 (42%) were performed in Guy's stone score (GSS) ≥ III stones. Median volume of treated stones was 120 mm3 (IQR 12-305). Among 33 surgeries, five (15%) were associated with intraoperative complications and 12 (36%) were associated with postoperative complications (Clavien-Dindo IIIa, n = 1, 3%). Residual stones were present in 12 (36%) surgeries. According to renal function, no differences were recorded between pre-operative and either 3-mo eGFR (p = 0.2) or 6-mo eGFR (p = 0.2). In this single-center European cohort, mini-ECIRS and mini-PCNL were feasible and safe treatment options for stones in SK patients, with acceptable postoperative outcomes. Nevertheless, larger prospective studies are needed to strengthen the current evidence.

PMID 42892643
Read full article →
PubMedDiagnostics (Basel, Switzerland)2026-10-16

Detection Strategies for HER2 and miR-21 in Breast Cancer: Current Approaches and Future Perspectives- Hybrid Systematic Review and Bibliometric Mapping.

Burța Diana-Maria DM, Cavalu Simona Daniela SD, Fritea Luminita L, Horvath Tunde T et al.

Background/Objectives: Breast cancer is still one of the main causes of mortality and morbidity at a global level, highlighting the need to identify robust biomarkers for early diagnosis, prognostic stratification and optimization of therapeutic decisions. Among these biomarkers, HER2 (Human Epidermal Growth Factor Receptor 2) and miR-21 represent the complementary levels of tumor biology, reflecting oncogenic signaling at the protein level and post-transcriptional regulation of gene expression. This hybrid systematic review and bibliometric mapping aims to critically analyze current methods for determining HER2 and miR-21 biomarkers, highlighting their advantages, limitations and clinical applicability, as well as future development directions in the field of precision oncology diagnostics. Methods: The bibliometric analyses were performed to investigate the intellectual structure, research trends, and collaboration patterns within the field of HER2 and miR-21 detection in breast cancer. A PRISMA-guided literature search was conducted in the Web of Science Core Collection (WoSCC), PubMed, and Scopus. After duplicate removal, screening, and eligibility assessment, 305 publications were included in the final review corpus. Bibliometric analyses of these 305 publications were performed using VOSviewer to investigate publication output, keyword co-occurrence, co-authorship, and institutional and country collaboration patterns. Results: Bibliometric analyses revealed the intellectual structure, research trends, and collaboration patterns within the field of HER2 and miR-21 detection in breast cancer. This work highlights the complementary role of HER2 and miR-21 biomarkers in breast cancer, highlighting their fundamental differences, but also their synergistic potential in clinical practice and translational research. A comparative analysis of detection methods highlights that, although conventional techniques remain the clinical standard, they are increasingly complemented by advanced technologies, such as digital PCR, optical and electrochemical biosensors. Conclusions: The emerging detection methods offer significant advantages in terms of sensitivity, rapidity and potential for miniaturization, but their clinical implementation is still limited by the lack of standardization and large-scale validation. A major bibliometric insight is the evident shift in publication output by country toward Asia, particularly China, India, and Iran, which currently show high publication output and extensive collaborative connectivity in the analyzed network. However, challenges remain in standardizing microRNA methods and the clinical validation of emerging technologies.

PMID 42882335
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about KD2-305